CA2371927A1 - Manipulation par l'oxide nitrique de l'activation de cellule satellite musculaire - Google Patents

Manipulation par l'oxide nitrique de l'activation de cellule satellite musculaire Download PDF

Info

Publication number
CA2371927A1
CA2371927A1 CA002371927A CA2371927A CA2371927A1 CA 2371927 A1 CA2371927 A1 CA 2371927A1 CA 002371927 A CA002371927 A CA 002371927A CA 2371927 A CA2371927 A CA 2371927A CA 2371927 A1 CA2371927 A1 CA 2371927A1
Authority
CA
Canada
Prior art keywords
muscle
nos
cells
skeletal muscle
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371927A
Other languages
English (en)
Inventor
Judy E. Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2371927A1 publication Critical patent/CA2371927A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans

Abstract

L'invention concerne des méthodes, des compositions pharmaceutiques et des trousses permettant de moduler l'activation du précurseur du muscle squelettique. Pour effectuer cette modulation, on utilise du monoxyde d'azote (NO), des donneurs de NO, des inhibiteurs d'activité du NO (inhibiteurs de NO) ou des régulateurs de production de NO, soit au niveau local, soit au niveau systémique. L'invention concerne également l'utilisation de NO, d'un donneur de NO, d'un inhibiteur de NO ou d'un régulateur de production de NO afin de moduler les effets des stéroïdes hormonaux sur le muscle squelettique. L'invention concerne également une méthode permettant d'identifier un composé qui provoque un changement de l'état d'activation des précurseurs du muscle. L'invention apporte un certain nombre d'avantages évidents. En permettant de manipuler directement les précurseurs du muscle squelettique, l'invention permet d'élaborer des traitements spécifiques afin de régénérer et de réparer le muscle.
CA002371927A 1999-03-11 2000-03-10 Manipulation par l'oxide nitrique de l'activation de cellule satellite musculaire Abandoned CA2371927A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12389599P 1999-03-11 1999-03-11
US60/123,895 1999-03-11
PCT/CA2000/000255 WO2000053191A2 (fr) 1999-03-11 2000-03-10 Modulation de l'activation du precurseur du muscle squelettique

Publications (1)

Publication Number Publication Date
CA2371927A1 true CA2371927A1 (fr) 2000-09-14

Family

ID=22411541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371927A Abandoned CA2371927A1 (fr) 1999-03-11 2000-03-10 Manipulation par l'oxide nitrique de l'activation de cellule satellite musculaire

Country Status (3)

Country Link
AU (1) AU3139500A (fr)
CA (1) CA2371927A1 (fr)
WO (1) WO2000053191A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
US7378438B2 (en) 2002-04-19 2008-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
WO2007088050A2 (fr) * 2006-02-03 2007-08-09 San Raffaele Centro Fond Procédé de traitement de la dystrophie musculaire
RU2429828C2 (ru) 2006-02-03 2011-09-27 Никокс С.А. Применение нитрооксипроизводного лекарственного средства для лечения мышечной дистрофии
WO2010108843A1 (fr) 2009-03-27 2010-09-30 Nicox S.A. Utilisation d'un dérivé nitro-oxy du paracétamol pour le traitement de dystrophies musculaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
WO1997033173A1 (fr) * 1996-03-08 1997-09-12 The Regents Of The University Of California Traitement et diagnostic de la dystrophie musculaire, de l'ictus et d'autres maladies neurodegeneratives
JPH10120654A (ja) * 1996-10-17 1998-05-12 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤

Also Published As

Publication number Publication date
WO2000053191A3 (fr) 2001-09-13
WO2000053191A2 (fr) 2000-09-14
AU3139500A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
KR101342971B1 (ko) 섬유화 억제를 위한 약물 담체 및 약물 담체 키트
Chen et al. Lack of integrin α1β1 leads to severe glomerulosclerosis after glomerular injury
Sáez et al. Gap junction hemichannels in astrocytes of the CNS
Zhu et al. Relationships between transforming growth factor-β1, myostatin, and decorin: implications for skeletal muscle fibrosis
Rochat et al. Insulin and wnt1 pathways cooperate to induce reserve cell activation in differentiation and myotube hypertrophy
Cornish et al. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development
EP2345455B1 (fr) Lacosamide déstiné au traitement de maladies lié à l'hyperexcitabilité en conjonction avec une malfonction des canaux sodiques
KR101708385B1 (ko) 골수 섬유증 치료제
Zagon et al. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor.
US20070015737A1 (en) Compounds for inhibiting diseases and preparing cells for transplantation
JP2003522107A (ja) 骨成長および毛成長を刺激するためのプロテアソーム活性のインヒビター
JP5566294B2 (ja) 筋肉再生治療用のラミニン−１を含む治療用医薬
US6967102B1 (en) Nitric oxide manipulation of muscle satellite cell activation
JP2013234193A (ja) 生理学的過程の調節およびこれに有用な薬剤
KR20220047888A (ko) 섬유화 조직으로부터 정상 조직을 재생하기 위한 조성물
Choi et al. Tonsil-derived mesenchymal stem cells incorporated in reactive oxygen species-releasing hydrogel promote bone formation by increasing the translocation of cell surface GRP78
EP3154580B1 (fr) Utilisation thérapeutique de modulateurs fonctionnels inhibant l'érythropoïétine
CA2371927A1 (fr) Manipulation par l'oxide nitrique de l'activation de cellule satellite musculaire
JP2001503446A (ja) 骨欠乏状態を治療するためのピペラジン誘導体
WO2014093632A2 (fr) Utilisation d'inhibiteurs de la cyclophiline d pour traiter ou prévenir des troubles osseux
Burke et al. In vitro aging of bovine and human retinal pigment epithelium: number and activity of the Na/K ATPase pump
CN110372779B (zh) 一种能保护及延长卵巢功能的多肽bpp及其应用
WO2017194975A1 (fr) Régénération musculaire
CN114632153A (zh) Hedgehog信号通路抑制剂在制备治疗异位骨化产品中的用途
US20030181374A1 (en) Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead